Brief: Tonix Pharmaceuticals Announces Peer-Reviewed Publication In Msphere Journal Highlighting The Tolerability Of Company’S Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
13/11/2024 14:06
Nov 13 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES PEER-REVIEWED PUBLICATION
IN
MSPHERE JOURNAL HIGHLIGHTING THE TOLERABILITY OF COMPANY’S
SINGLE-DOSE MPOX AND SMALLPOX VACCINE CANDIDATE TNX-801, IN
IMMUNE-COMPROMISED ANIMALS
* TONIX PHARMACEUTICALS HOLDING CORP - TNX-801 TOLERABILITY
IN
IMMUNE-COMPROMISED ANIMALS SUPPORTS CLINICAL DEVELOPMENT
Source text: ID:nGNX57thVv
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview